Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05537220 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oral N-acetylcysteine for Retinitis Pigmentosa

Study acronym: NAC Attack
StatusActive, Not Recruiting
PhasePhase 3
Started2023-10-11
View on ClinicalTrials.gov ↗

Amendment history

2026-06-12
2 amendments v43-v44
2 re-verifications since 2026-05-01, no change to tracked fields
2026-02-26
Study Status, Study Design v42
Completion date2029-05→2030-05
Enrollment targetestimated 483→confirmed 485
2026-01-09
Study Status v41
Re-verified, no change to tracked fields
2025-09-26
Enrolling by Invitation→Active, Not Recruiting Study Status v40
Trial statusEnrolling by Invitation→Active, Not Recruiting
2025-09-26
2 amendments v38-v39
2 re-verifications since 2025-08-07, no change to tracked fields
Show 37 earlier versions
2025-08-06
Active, Not Recruiting→Enrolling by Invitation Study Status v37
Trial statusActive, Not Recruiting→Enrolling by Invitation
2025-07-31
Study Status v36
Re-verified, no change to tracked fields
2025-06-18
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v35
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 31 of 31 sites
2025-05-30
Study Status, Contacts/Locations v34
Study sitescontacts updated at 1 of 31 sites
2025-05-23
Study Status, Sponsor/Collaborators, Study Description, Study Design, Contacts/Locations v33
Primary completion date2028-12→2029-05
Completion date2028-12→2029-05
Enrollment target438→483
Study sites32→31
Collaborators32 to 31 entries
Centro Medico ABC
2025-04-01
Study Status, Contacts/Locations v32
Study sitescontacts updated at 1 of 32 sites
2025-01-31
Study Status, Contacts/Locations v31
Study sitescontacts updated at 1 of 32 sites
2024-12-12
Study Status, Contacts/Locations v30
Study sitescontacts updated at 1 of 32 sites
2024-12-09
Study Status, Contacts/Locations v29
Study sitescontacts updated at 1 of 32 sites
2024-11-08
Study Status, Contacts/Locations v28
Study sites31→32
2024-11-07
Study Status, Contacts/Locations v27
Study sitescontacts updated at 1 of 31 sites
2024-09-05
Study Status, Contacts/Locations v26
Study sitescontacts updated at 1 of 31 sites
2024-08-22
Study Status, Contacts/Locations v25
Study sites31 entries, revised
Medical University of Graz, Department of OpthalmologyOphthalmology
2024-04-11
Study Status, Contacts/Locations v24
Study sitesdetails revised at 1 of 31 sites
2024-04-01
Study Status, Contacts/Locations v23
Study sitesdetails revised at 1 of 31 sites
2024-03-12
Study Status, Contacts/Locations v22
Study sitesdetails revised at 1 of 31 sites
2024-02-21
Study Status, Contacts/Locations v21
Study sitesdetails revised at 1 of 31 sites
2024-02-19
Study Status, Outcome Measures, Contacts/Locations, IPDSharing v20
Study sitesdetails revised at 1 of 31 sites
2024-02-12
Study Status, Contacts/Locations v19
Study sitesdetails revised at 1 of 31 sites
2024-01-29
Study Status, Contacts/Locations v18
Study sitesdetails revised at 4 of 31 sites
2023-12-21
Study Status, Contacts/Locations v17
Study sitesdetails revised at 3 of 31 sites
2023-12-08
Study Status, Contacts/Locations v16
Study sitesdetails revised at 2 of 31 sites
2023-12-03
Study Status, Contacts/Locations v15
Study sitesdetails revised at 1 of 31 sites
2023-11-30
Study Status, Contacts/Locations v14
Study sitesdetails revised at 2 of 31 sites
2023-11-17
Study Status, Contacts/Locations v13
Study sitesdetails revised at 1 of 31 sites
2023-11-07
Study Status, Contacts/Locations v12
Study sitesdetails revised at 1 of 31 sites
2023-11-06
Study Status, Contacts/Locations v11
Study sitesdetails revised at 1 of 31 sites
2023-10-25
Study Status, Contacts/Locations v10
Study sitesdetails revised at 1 of 31 sites
2023-10-19
Study Status, Contacts/Locations v9
Study sitesdetails revised at 1 of 31 sites
2023-10-12
Study Status v8
Start dateestimated 2023-10-09→confirmed 2023-10-11
2023-10-06
Not Yet Recruiting→Recruiting Study Status, Sponsor/Collaborators, Contacts/Locations v7
Trial statusNot Yet Recruiting→Recruiting
Start date2023-10→2023-10-09
Study sites31 entries, revised
UniversityScheie ofEye Illinois - Chicago, UI HealthInstitute
Collaborators32 entries, revised
University of Illinois at ChicagoPennsylvania
2023-09-08
Study Status v6
Start date2023-09→2023-10
2023-08-07
Study Status v5
Primary completion date2028-11→2028-12
Completion date2028-11→2028-12
Start date2023-08→2023-09
2023-07-12
Study Status, Contacts/Locations v4
Re-verified, no change to tracked fields
2023-06-08
Study Status v3
Primary completion date2028-03→2028-11
Completion date2028-03→2028-11
Start date2023-06→2023-08
2023-02-09
Study Status v2
Start date2023-02→2023-06
2022-09-19
Study Status, Contacts/Locations v1
Study sites31 entries, revised
DukeWilmer Eye Institute- Johns Hopkins University
2022-09-08
Original filing
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes to cone degeneration. N-acetylcysteine (NAC) reduces oxidative stress and in animal models of RP it slowed cone degeneration. In a phase I clinical trial in patients with RP, NAC taken by month for 6 months caused some small improvements in two different vision tests suggesting that long-term administration of NAC might slow cone degeneration in RP. NAC Attack is a clinical trial being conducted at many institutions in the US, Canada, and Europe designed to determine if taking NAC for several years provides benefit in patients with RP.
Trial Details
NCT Number NCT05537220
Lead Sponsor Johns Hopkins University
Collaborators: National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Conditions Retinitis Pigmentosa
Enrollment 485 participants
Start Date 2023-10-11
Primary Completion 2029-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-15